Overview

Nivolumab Plus Stereotactic Body Radiotherapy in II and III Line of Patients With Metastatic Renal Cell Carcinoma

Status:
Active, not recruiting

Trial end date:
2021-07-14

Target enrollment:

Participant gender:

Summary

NIVES study is an ongoing phase II, single arm, multicenter study. In this trial pts received SBRT to one non-brain measurable lesion and concomitant NIVOLUMAB, an anti-programmed cell death (PD-1). Combining SBRT with NIVO may enhance the antitumor immune responses and improve clinical outcomes, how it was demonstrated for other solid tumors with a phenomenon known as the abscopal effect . It was planned to enrolled a total of 68 pts within 12 months. The objective of the current analysis is to describe the first report of safety profile of NIVO in combination with SBRT.

Phase:

Phase 2

Details

Lead Sponsor:

Gruppo Oncologico Italiano di Ricerca Clinica

Treatments:

Antibodies, Monoclonal
Nivolumab